Advances in medical imaging for the diagnosis and management of common genitourinary cancers |
| |
| Authors: | Mohammad H Bagheri Mark A Ahlman Liza Lindenberg Baris Turkbey Jeffrey Lin Ali Cahid Civelek Ashkan A Malayeri Piyush K Agarwal Peter L Choyke Les R Folio Andrea B Apolo |
| |
| Institution: | 1. Clinical Image Processing Service, Radiology and Imaging Sciences Department, Clinical Center, National Institutes of Health, Bethesda, MD;2. Nuclear Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD;3. Radiology and Imaging Sciences Department, Clinical Center, National Institutes of Health, Bethesda, MD;4. Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;5. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;6. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD |
| |
| Abstract: | Medical imaging of the 3 most common genitourinary (GU) cancers—prostate adenocarcinoma, renal cell carcinoma, and urothelial carcinoma of the bladder—has evolved significantly during the last decades. The most commonly used imaging modalities for the diagnosis, staging, and follow-up of GU cancers are computed tomography, magnetic resonance imaging (MRI), and positron emission tomography (PET). Multiplanar multidetector computed tomography and multiparametric MRI with diffusion-weighted imaging are the main imaging modalities for renal cell carcinoma and urothelial carcinoma, and although multiparametric MRI is rapidly becoming the main imaging tool in the evaluation of prostate adenocarcinoma, biopsy is still required for diagnosis. Functional and molecular imaging using 18-fluorodeoxyglucose-PET and sodium fluoride-PET are essential for the diagnosis, and especially follow-up, of metastatic GU tumors. This review provides an overview of the latest advances in the imaging of these 3 major GU cancers. |
| |
| Keywords: | Renal cell carcinoma Bladder urothelial carcinoma Prostate adenocarcinoma CT MRI PET |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
